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The bile pigments, biliverdin, and bilirubin, are endogenously derived substances gener-
ated during enzymatic heme degradation. These compounds have been shown to act as
chemical antioxidants in vitro. Bilirubin formed in tissues circulates in the serum, prior to
undergoing hepatic conjugation and biliary excretion. The excess production of bilirubin
has been associated with neurotoxicity, in particular to the newborn. Nevertheless, clinical
evidence suggests that mild states of hyperbilirubinemia may be beneﬁcial in protect-
ing against cardiovascular disease in adults. Pharmacological application of either bilirubin
and/or its biological precursor biliverdin, can provide therapeutic beneﬁt in several animal
models of cardiovascular and pulmonary disease. Furthermore, biliverdin and bilirubin can
confer protection against ischemia/reperfusion injury and graft rejection secondary to organ
transplantation in animal models. Several possiblemechanisms for these effects have been
proposed, including direct antioxidant and scavenging effects, and modulation of signaling
pathways regulating inﬂammation, apoptosis, cell proliferation, and immune responses.The
practicality and therapeutic-effectiveness of bile pigment application to humans remains
unclear.
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INTRODUCTION
Natural antioxidants constitute an important part of host defenses
against environmental exposure to noxious agents (Davies, 1995).
Pro-oxidant states arise when reactive oxygen species (ROS)
formed during metabolism exceed cellular antioxidant capacity
(Davies, 1995). Although ROS act as mediators of cellular homeo-
static regulation and signaling (Forman et al., 2010), excessive ROS
production may contribute to the pathogenesis of human diseases,
including cancer, and cardiovascular diseases (CVD; Dröge, 2002;
Valko et al., 2006; Sugamura and Keaney, 2011). Cells contain
water and lipid soluble chemicals and antioxidant enzymes that
function to limit harmful oxidative reactions and preserve tissue
homeostasis (Halliwell and Gutteridge, 1999; Davies, 2000). Addi-
tionally, many dietary substances can be absorbed and serve as
systemic antioxidants (Kaliora et al., 2006; García-Lafuente et al.,
2009). Thus,much research has been directed toward the exploita-
tionof naturally occurring antioxidant compounds as therapeutics
in the prevention or treatment of human disease (Kaliora et al.,
2006; García-Lafuente et al., 2009; Sugamura and Keaney, 2011).
The bile pigments biliverdin (BV) and bilirubin (BR) origi-
nate as the products of heme degradation (Roy-Chowdhury et al.,
2008;Figure 1). These pigments have been regardedby themedical
community as waste products of metabolism (Vitek and Ostrow,
2009). However, BV/BR exhibit antioxidant properties in model
systems (Stocker et al., 1987a). Circulating BR acts as a potent
serum antioxidant, and serves as a natural anti-atherogenic fac-
tor (Stocker et al., 1987b). Retrospective and prospective clinical
studies indicate that mildly elevated levels of BR (mild hyper-
bilirubinemia) are associated with reduced CVD risk (Franchini
et al., 2010). Beneﬁcial effects of pharmacological BR/BV have
been described in pre-clinical models of tissue injury and disease,
including organ transplantation, lung disease, and CVD (Ollinger
et al., 2007; Ryter et al., 2007). These effects involve antioxidant,
anti-inﬂammatory, anti-apoptotic, and anti-proliferative mech-
anisms (Ollinger et al., 2007; Ryter et al., 2007). This review
discusses the therapeutic application of the BR/BV in disease, as
well as clinical data on the role of endogenous BR as an inverse
risk factor for CVD.
ORIGIN AND METABOLIC FATE OF BILIRUBIN
Bilirubin formed in vivo originates from hemoglobin turnover
(∼80%) during the degradation of erythrocytes by reticuloen-
dothelial macrophages. The remainder of BR formation results
from hemoprotein turnover in systemic tissues. Biliverdin-IXα
(BV-IXα), the precursor to BR, is a water soluble pigment that
originates during heme degradation catalyzed by heme oxygenase
activity (HO; E.C. 1:14:99:3), represented by constitutive (HO-2)
and inducible (HO-1) isozymes (Tenhunen et al., 1969; Maines,
1997).
Heme oxygenase activity, the rate-limiting step in heme degra-
dation, requires three moles O2 per heme oxidized, and electrons
from NADPH cytochrome-p450 reductase (Yoshida and Kikuchi,
1974; Noguchi et al., 1979; Yoshida et al., 1980). Each mole of
BV-IXα formed yields one mole each of carbon monoxide (CO),
derived from the heme α-methene carbon, and ferrous iron (Ten-
hunen et al., 1969). BV-IXα is reduced to bilirubin-IXα (BR-IXα),
a lipid soluble pigment, by NADH/NADPH-dependent biliverdin
reductase (BVR; E.C. 1.3.1.24; Tenhunen et al., 1970).
Bilirubin follows a sequence of biological transformation and
elimination steps (Figure 2). BR formed in situ passes to the
serum where it circulates in a complex with serum albumin (Roy-
Chowdhury et al., 2008; Vitek and Ostrow, 2009). A fraction
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FIGURE 1 | Sequence of bile pigment formation and degradation. Heme
Oxygenase (HO) degrades heme to biliverdin-IXα (BV), in a reaction
generating carbon monoxide (CO) and ferrous iron, at the expense of NADPH
and molecular oxygen. BV is reduced to bilirubin-IXα (BR) by NAD(P)H
biliverdin reductase (BVR). BR is conjugated with glucuronic acid at its
propionyl side chains by hepatic UDP-glucuronyltransferase-1A1 (UGT1A1), to
form BR mono- and di-glucuronides. BR can be further metabolized to
urobilinogen by intestinal microﬂora.
of serum unconjugated BR circulates freely (∼0.01%; Vitek and
Ostrow, 2009). Unconjugated BR is taken up by the liver by facili-
tated diffusion, involving organic ion transporters (e.g., SLCO1B1;
Kamisako et al., 2000;Cui et al., 2001). The intracellular hepatocyte
transport of BR is assisted by ligandin, a complex of glutathione-
S-transferase (GST) subunits, and by protein-Z (Litwack et al.,
1971). BR is conjugated in hepatocytes by uridine diphosphate
(UDP) glucuronyltransferase (UGT1A1; EC: 2.4.1.17; Chowd-
hury et al., 1979). Conjugated BR (mono- and di-glucuronides)
is pumped from hepatocytes across the canalicular membrane
by multidrug resistance protein-2 and excreted through the bile
to the intestine (Chowdhury and Chowdhury, 1983; Wang et al.,
2006a).
ANTIOXIDANT EFFECTS OF BILE PIGMENTS
The potential for the use of bile pigments as therapeutics orig-
inated with the discovery that these substances act as natural
antioxidants. Stocker et al. demonstrated that BV, BR, and con-
jugated BR inhibit lipid peroxidation in liposomal preparations
challenged with free radical initiating chemicals (Stocker and
Ames, 1987; Stocker et al., 1987a; Stocker and Peterhans, 1989a).
In these model systems, BR and BV exerted chain-breaking and
peroxyl radical trapping activity (Stocker and Ames, 1987; Stocker
et al., 1987a). BV and conjugated BR acted as co-antioxidants with
α-tocopherol, and inhibited α-tocopherol consumption (Stocker
and Peterhans, 1989a). BR also prevented oxidative damage to pro-
teins, such as serum albumin exposed to ROS-generating systems
(Stocker et al., 1987b;Neuzil andStocker,1993). Free and albumin-
bound BR inhibited oxidation of LDL-bound lipids, by acting as
co-antioxidants with the LDL-bound α-tocopherol (Neuzil and
Stocker, 1994).
Bilirubin can reactwith superoxide anion radical,hypochlorous
acid, and singlet molecular oxygen, inhibit the photo-oxidation of
protein, and inhibit chemiluminescence in activated macrophages
(Stevens and Small, 1976; Pedersen et al., 1977; Stocker and Peter-
hans, 1989b). BR can also react with NO or reactive nitrogen
species (RNS; Kaur et al., 2003; Mancuso et al., 2003). Finally, con-
jugated BR forms a cupric complex that promotes decomposition
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FIGURE 2 | Biodistribution of BR. BR is generated in systemic tissues as
the product of hemoprotein (i.e., hemoglobin) degradation. BR formed in
tissues passes freely to the circulation, where it exists mostly in a complex
with serum albumin. BR is taken up by hepatocytes by facilitated diffusion.
In the hepatocyte, BR is transported by glutathione-S-transferase (GST),
and then conjugated by UDP-glucuronyltransferase-1A1 (UGT1A1) to form
bilirubin di-glucuronide (BR-dG). Conjugated BR (BR-dG) is then pumped
into the bile duct and reaches the intestine. Conjugated BR can be
reabsorbed in the intestine and re-enter the circulation (Roy-Chowdhury
et al., 2008; Vitek and Ostrow, 2009). The metabolism of BR in the intestine
by bacterial action generates urobilinogen (UB) and its oxidation product
urobilin, the latter which is eliminated in the feces. Intestinal urobilinogen
can be reabsorbed by the intestine and eliminated in the urine as urobilin
(Chowdhury and Chowdhury, 1983;Wang et al., 2006a).
of hydroperoxides, representing a pro-oxidant activity in the bile
(Stocker and Ames, 1987).
Bilirubin serves as circulating antioxidant in human plasma.
The treatment of plasma with oxidizing agents resulted in the
depletion of endogenous antioxidants in the order ubiquinol-10,
ascorbate, and bilirubin. The addition of BR to human plasma
after depletion of naturally occurring antioxidants resulted in the
inhibition of lipid peroxidation, and reduction of α-tocopherol
consumption (Neuzil and Stocker, 1994). Serum samples from
hyperbilirubinemic patients with Gilbert’s syndrome were resis-
tant to oxidation and displayed higher total antioxidant capacity
than serum from subjects in the normal range of BR concentration
(Bulmer et al., 2008).
Exogenous BR when applied pharmacologically to cultured
cells can provide dose-dependent cytoprotection against oxidative
stress (Clark et al., 2000a). For example, BR (1–5μM) protected
cultured vascular smooth muscle cells against cytotoxicity from
enzyme-generated H2O2 (Clark et al., 2000a). BR when applied
at nanomolar concentrations protected primary neurons against
cytotoxicity caused by exogenous H2O2 (Doré et al., 1999).
Despite evidence suggesting that extracellular BR can act as a
cytoprotectant, the role of BR as a cellular antioxidant remains
unclear. BR produced in situ is secreted to the circulation, conju-
gated in the liver, and excreted (Roy-Chowdhury, 1996). However,
the fraction of BR that is retained in cells to serve a membrane
antioxidant function is unknown. A common argument against
a cellular antioxidant role for BR is that the cellular milieu
contains efﬁcient and abundant endogenous antioxidant com-
pounds, including millimolar quantities of reduced glutathione
(GSH; Meister and Anderson, 1983), ascorbate, β-carotene, and
α-tocopherol (Halliwell and Gutteridge, 1999). Given that BR is
exported and eliminated, the relative contribution of BR to cel-
lular antioxidant capacity in the presence of other endogenous
antioxidants remains unclear.
Current evidence for the role of BR as a cellular antioxidant is
based on evidence using siRNA studies targeting BVR, the enzyme
responsible for BR formation. Knockdown of BVR sensitized cells
to high concentrations of H2O2 (Baranano et al., 2002), and to
arsenite-mediated apoptosis (Miralem et al., 2005). In the latter
case, similar effects were not achieved with HO-1 knockdown,
suggesting effects of BVR independent of BR generation (Miralem
et al., 2005).
Snyder et al. observed that BV is formed during the oxidation of
BR (Baranano et al., 2002). The authors proposed that BV formed
by BR oxidation would act as a substrate for BVR, to regener-
ate BR, and thus represent a self-perpetuating antioxidant system,
“the BVR antioxidant cycle.” Evidence for and against this path-
way has been debated elsewhere (Maghzal et al., 2009; Sedlak and
Snyder, 2009; Stocker and Maghzal, 2009). It remains unclear if
BV regenerated during the oxidation of BR would exceed but a
minor fraction, and whether this would contribute signiﬁcantly to
cellular antioxidant capacity as proposed.
TOXICITY OF BILIRUBIN
Bilirubin accumulation can be harmful, especially in infants with
neonatal hyperbilirubinemia. The selective toxicity of BR to the
neonate is due to incomplete establishment of the blood–brain
barrier. Neonatal unconjugated hyperbilirubinemia is associated
with severe neurological side effects, which include neurologi-
cal encephalopathy and kernicterus (Vitek and Ostrow, 2009). To
avoid risk of neurotoxicity, phototherapy is applied to reduce the
levels of unconjugated BR in jaundiced newborns (Blanckaert and
Fevery, 1990). The mechanisms of BR toxicity in the brain have
been reviewed elsewhere (Brito et al., 2008; Ghersi-Egea et al.,
2009; Tell and Gustincich, 2009; Vitek and Ostrow, 2009).
PROTECTIVE EFFECTS OF BILE PIGMENTS IN ANIMAL MODELS OF
TISSUE INJURY
Excluding neonatal toxicity, mild hyperbilirubinemia, due to ele-
vated serum antioxidant capacity, may confer beneﬁts to the host.
In a mouse model of hyperbilirubinemia, jaundiced Gunn rats
displayed lower indices of oxidative stress in the serum than
wild-type mice when challenged with hyperoxia (Dennery et al.,
1995).
Therapeutic application of BR preserved myocardial function
during cardiac ischemia/reperfusion (I/R) injury (Clark et al.,
2000b). In an isolated perfused heart model, heme precondition-
ing protected against myocardial infarction following I/R injury,
associated with increased HO-1 expression and BR formation.
Administration of BR at nanomolar concentrations improved car-
diac performance and reduced infarct size and mitochondrial
dysfunction following I/R injury (Clark et al., 2000b)
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Injection of BV decreased pro-inﬂammatory cytokines
production (i.e., IL-6), upregulated IL-10 levels, and reduced
inﬂammatory lung injury in rats challenged with lipopolysac-
charide (LPS). Thus, BV protected against systemic inﬂamma-
tion and lung injury after lethal exposure to LPS. The protective
effects of BV against LPS-induced injury were observed in cul-
tured lung endothelial cells and macrophages (Sarady-Andrews
et al., 2005). Additional anti-inﬂammatory effects of BR have been
reported in cell culture. For example, BR inhibited TNF-α depen-
dent expression of adhesion molecules (i.e., E-selectin, VCAM-1,
ICAM-1) in endothelial cells (Mazzone et al., 2009). Recently,
enhanced nuclear translocation of BVR has been implicated in
the anti-inﬂammatory effects of BV (Wegiel et al., 2011).
Bilirubin can act as an inhibitor of smooth muscle cell pro-
liferation (Nakao et al., 2005; Ollinger et al., 2005). Exogenous
BV administration inhibited neointimal hyperplasia associated
with vascular injury in rats (Nakao et al., 2005; Ollinger et al.,
2005). These effects were attributed to downregulation of JNK,
and inhibition of endothelial cell apoptosis (Nakao et al., 2005).
Similarly, hyperbilirubinemic animals were resistant to vascular
injury (Ollinger et al., 2005). The anti-proliferative effects of BV
and BR were demonstrated in vascular smooth muscle cell culture.
Exogenous BV/BR arrested cells in G1 phase after serum stimula-
tion, associated with inhibition of p38 MAPK and retinoblastoma
protein phosphorylation (Ollinger et al., 2005).
Experimental hyperbilirubinemia (3–10 mg/dl) induced by
infusion protected against bleomycin-induced pulmonary ﬁbro-
sis in rats (Wang et al., 2002). BR-infused rats displayed reduced
lung injury in response to bleomycin challenge, including lowered
lung hydroxyproline content, reduced polymorphonuclear lym-
phocyte and leukocyte counts, and reduced levels of transforming
growth factor-β in bronchoalveolar lavage (Wang et al., 2002).
Thus, the anti-ﬁbrotic effects of BR may relate to both antioxidant
and anti-proliferative effects of this pigment.
Recent studies have also implied a protective effect of BV/BR
in diabetes. Application of BV to streptozotocin induced diabetic
rats reduced urinary isoprostanes, and protected against endothe-
lial cell sloughing (Rodella et al., 2006). BR ameliorated diabetic
nephropathy, through the reduction of cytosolic ROS generation
and anti-inﬂammatory effects (Fujii et al., 2010). Hyperbiliru-
binemic mice, or BV-treated diabetic mice, displayed reduced
albuminuria, and urinary markers of oxidative stress relative to
wild-type or untreated controls, respectively. Application of BV or
BR inhibited ROS production in endothelial and mesangial cells
induced by high glucose or angiotensin-II exposure (Fujii et al.,
2010).
PROTECTIVE EFFECTS OF BILE PIGMENTS IN ORGAN
TRANSPLANTATION
Therapeutic effects of exogenously applied bile pigments have
been described in animal models of organ transplantation and
acute graft rejection, including liver (Fondevila et al., 2004), kidney
(Adin et al., 2005), and heart (Yamashita et al., 2004) trans-
plantation. In the isolated perfused kidney, perfusion with BR
protected against warm I/R-induced tissue injury and preserved
renal function (Adin et al., 2005). BV provided tissue protec-
tion in an ex vivo model of cold hepatic I/R injury. Furthermore,
inclusion of BV in the perfusate increased survival in rats subjected
to orthotopic liver transplantation by preserving liver function
(Fondevila et al., 2004). This protection conferred by BV was asso-
ciated with decreased expression of pro-inﬂammatory indices,
including neutrophil inﬂux, pro-inﬂammatory cytokine expres-
sion, and iNOS activation (Fondevila et al., 2004). BV treatment
improved survival of rat cardiac allografts, by reducing leukocyte
inﬁltration and inhibiting T-cell proliferation (Yamashita et al.,
2004). In transplant-associated cold I/R injury of heart and kid-
ney grafts, the application of BV simultaneously with CO provided
a synergistic tissue protection,whereas lesser effects were observed
with either test agent alone (Nakao et al., 2000). BV also prevented
rejection of lung grafts from brain-dead donors, which are more
prone to rejection (Zhou et al., 2011). In allogeneic islet trans-
plantation, treatment of the donor or the donor graft ex vivo with
BR improved islet graft survival. Treatment of the recipient with
BR also improved the survival of islet grafts (Wang et al., 2006b;
Zhu et al., 2010). BR conferred transplant tolerance to islet grafts
by up-regulating regulatory T cells (Lee et al., 2007). The anti-
apoptotic and anti-inﬂammatory effects of BV/BR observed in I/R
injurymodelsmay contribute to protection during I/R injury asso-
ciated with transplantation. These experiments also suggest that
pharmacological BR may have immunomodulatory functions that
contribute to therapeutic effects in the setting of graft rejection
(Ollinger et al., 2007).
BILIRUBIN IN CARDIOVASCULAR AND LUNG DISEASE
Recent clinical studies have reported inverse associations between
serum BR levels and the risk factors associated with CVD. These
studies collectively suggest that natural elevations in serum BR
confer protection against CVD, including atherosclerosis, coro-
nary artery disease (CAD)/ischemic heart disease (IHD), diabetes,
and stroke (Novotný and Vítek, 2003; Franchini et al., 2010).
In one of the ﬁrst studies reporting associations between BR
and CVD, a study of 619 males adjusted for age-dependent risk
factors, the level of serum BR was described as an inverse risk fac-
tor for CAD (Schwertner et al., 1994). BR was weakly predictive
for CAD relative to lipoprotein markers (Levinson, 1997). Never-
theless, a strong correlation between BR levels and apolipoprotein
B levels, a risk factor for atherosclerosis, was reported (Levinson,
1997). Serum BR levels represented an inverse risk factor for CAD
in subjects with early familial CAD (Hopkins et al., 1996).
In a large-scale prospective study (7,685 men), subjects in the
midrange of serum BR concentration displayed reduced risk of
IHD, relative to subjects in the lowest quintile of serum BR distri-
bution (Breimer et al., 1995). Individuals in the lowest BR quintile
exhibited reduced high density lipoprotein (HDL) cholesterol, and
reduced lung function. Although midlevel serum BR was associ-
ated with reduced CVD risk, the hyperbilirubinemic individuals
(highest quintile) exhibited a similar risk of IHD as individuals in
the lowest serum BR quintile (Breimer et al., 1995).
Serum BR levels have been indicated as an independent, inverse
risk factor for peripheral vascular disease (Breimer et al., 1994). In
large-scale cross-sectional studies, serum BR levels within the nor-
mal rangewere inversely associatedwith risk of peripheral vascular
disease (Perlstein et al., 2008a) and stroke (Perlstein et al., 2008b).
A 1.71μM increase in BR level was associated with 6% reduction
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in the odds of peripheral vascular disease (7,075 participants; Perl-
stein et al., 2008a), and 9% reduction in the odds of stroke (13,214
participants; Perlstein et al., 2008b).
In 72 healthy subjects, serum BR levels were inversely corre-
lated with indicators for atherosclerosis (Erdogan et al., 2005).
Low serum BR levels were associated with increased carotid artery
intimal-medial thickness, and impaired ﬂow-mediated vasodila-
tion, indicative of endothelial dysfunction (Erdogan et al., 2005).
Furthermore, BR levels were inversely correlated to carotid plaque
formation in 1,774 subjects, with a reported odds ratio of 0.37 for
an increase of 17.1 μM increase in BR (Ishizaka et al., 2001).
In a cross-sectional study of 2,307 Koreans, total and direct BR
levels were inversely correlated to plasma levels of C-reactive pro-
tein (CRP), an indicator of vascular inﬂammation (Hwang et al.,
2011). Similar inverse associations were reported between BR and
levels of high sensitivity (hs)-CRP (Gullu et al., 2005;Yoshino et al.,
2011). BR was inversely correlated with CVD in patients with
hypercholesterolemia, and elevated in patients receiving statins
(Nolting et al., 2011).
A prospective study (Framingham offspring study, 5,124 par-
ticipants) concluded that a higher concentration of total serum
BR was associated with lower risk of CVD in men, with unclear
association for women (Djousse et al., 2001). This study revealed
a higher risk of myocardial infarction for both men and women
associated with low serum BR and low serum albumin (Djoussé
et al., 2003).
Bilirubin levels have been examined as an independent predic-
tor of CVD mortality. No association was found between serum
BR and all-cause CVD mortality in a 10 year study of the Belgian
population, although increased BR was associated with reduced
cancer mortality in males (Temme et al., 2001). However, in a
recently published study of 1,279 men, BR levels and cardiopul-
monary ﬁtness level was independently and negatively correlated
to all-cause and CVD mortality (Ajja et al., 2011).
Additional studies have analyzedpotential associations between
BR levels and CVD-related diseases such as diabetes (Ko et al.,
1996; Fukui et al., 2008, 2011; Cheriyath et al., 2010) and metabolic
syndrome (Jo et al., 2011;Kwon et al., 2011).A large cross-sectional
study (15,876 subjects) reported an inverse association between
total BR and diabetes risk (Cheriyath et al., 2010). Patients with
type II diabetes on hemodialysis displayed an increased risk of
CVD associated with low serum BR, relative to diabetic patients
not on hemodialysis (Fukui et al., 2011). Serum BR was inversely
correlated with albuminuria in Type II diabetic patients (Fukui
et al., 2008). In a Chinese cohort (1,508 subjects), low serum
BR was associated with aberrations in glucose tolerance, and
increases in CVD risk factors including triglycerides, very-low
density lipoprotein, and glycated hemoglobin (Ko et al., 1996).
Additional studies have examined associations of BR with CVD
in hyperbilirubinemia originating from metabolic disorders of BR
metabolism. A TA repeat polymorphism of the UTG1A1 gene
promoter (designated UGT1A1∗28, or TA7) results in reduced
transcription of UTG1A and deﬁcit in hepatic BR conjugation
and clearance (Schwertner and Vítek, 2008). Individuals homozy-
gous for UGT1A1∗28 (TA7/TA7) display a hyperbilirubinemia,
referred to as Gilbert’s syndrome, relative to wild-type subjects
(TA6/TA6) or heterozygotes. A sixfold reduced risk of IHD and
elevated HDL cholesterol was reported in a study of 50 Gilbert’s
patients relative to the general population (Vítek et al., 2002).
In Gilbert’s patients, unconjugated BR was negatively correlated
with small dense low density lipoprotein cholesterol sd-LDL-C,
oxidized LDL and hs-CRP (Tapan et al., 2011).
In the Framingham Heart study homozygote carriers for the
UGT1A1∗28 allele with elevated serum BR concentrations dis-
played a strong association with lower CVD risk (Lin et al., 2006).
These observations were further validated by conditional linkage
and genome-wide association studies. These studies concluded
that UTG1A is a major gene linked to CVD, and that the TA repeat
polymorphism is strongly associated with reduced CVD risk (Lin
et al., 2009). In a study of peripheral arterial disease, no association
of UGT1A1 polymorphisms was observed, despite inverse corre-
lation of CVD risk with BR levels (Rantner et al., 2008). Recent
post-mortem studies also reported that UGT1A1 polymorphisms
were not correlated with severity of CAD (Papez et al., 2009).
Finally, BR was inversely associated with risk of lung disease.
In a cohort study (504,206 subjects) each 0.1-mg/dL increase in
BR in males was associated with 9%, and 6% decreases in the
risk of lung cancer, and chronic obstructive pulmonary disease,
respectively (Horsfall et al., 2011).
CONCLUSION
Biliverdin and BR are naturally occurring substances derived from
heme catabolism that possess antioxidant properties. Further-
more, circulating BR can contribute to serumantioxidant capacity.
In pre-clinical studies, pharmacological application of BR con-
fers protection against I/R injury, acute lung injury, pulmonary
ﬁbrosis, renal injury, and graft rejection. Several limitations of
the therapeutic applications of bile pigments must be considered.
Although BV is soluble in aqueous media, BR is lipophilic and
soluble only in organic solvents, thereby posing challenges for
therapeutic delivery.
Bilirubin is the by-product of the heme degradation pathway,
and thereby may mediate the cytoprotective properties of HO-1
(Foresti et al., 2004). Pharmacological or gene therapy approaches
involving the targeted expression of HO-1 are under develop-
ment (Abraham et al., 2007). However, these approaches are not
speciﬁc for BV/BR generation, since modulation of HO-1 has
pleiotropic effects that impact systemic iron metabolism and CO
generation. Similarly, targeted expression of BVR may affect cel-
lular signaling pathways independently of its role in bile pigment
generation (Kapitulnik and Maines, 2009). Clinical studies have
suggested inverse associations between serum BR and CVD risk.
Mild hyperbilirubinemia may reduce CVD risk, but this awaits
further validation. To date, there remain no practical methodolo-
gies for inducing hyperbilirubinemia for clinical beneﬁt. Despite
therapeutic beneﬁt in animal tissue injury models, the therapeutic
potential of BR remains untested in humans.
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